IONIC Trial Progresses as Veyonda Passes Safety Milestone

Highlights

- **Veyonda® passes safety milestone**
- **Safety Steering Committee review found Veyonda safe at 1200mg dose**
- **IONIC trial seeking to increase activity of immune checkpoint inhibitors for cancer patients through combination of Veyonda® with Bristol Myers Squibb's Opdivo® (nivolumab)**

Sydney 2 December 2022: Innovative Australian biotech **Noxopharm Limited (ASX:NOX)** provides an update on the IONIC Investigator-initiated pilot Phase 1 trial of its lead oncology drug candidate Veyonda®.

IONIC is exploring the potential of Veyonda to increase the activity of Bristol Myers Squibb's immune checkpoint inhibitor Opdivo® (nivolumab) in different types of cancer.

The IONIC Safety Steering Committee has reviewed the safety data from all evaluable patients in the trial. The 1200 mg dose was found to be safe and well tolerated, allowing enrolment to continue with the next patient cohort to be treated with an increased Veyonda® dose of 1800 mg.

There are now six active sites in the Sydney area and regional NSW. The enrolment rate is proceeding according to the schedule, with 11 patients now enrolled and others in screening.

This trial is being led by principal investigator Professor Paul de Souza, who has research agreements with BMS and Noxopharm to conduct the trial, administering both Veyonda and Opdivo to an ultimate target of approximately 30 patients.

Professor de Souza said: "The investigation of checkpoint inhibitor resistance is very important at a time when more and more patients are receiving these drugs. We are making good progress with this trial, and look forward to treating this next cohort of patients at the higher dose level."

Noxopharm CEO Dr Gisela Mautner said: "We're pleased that the enrolment of this trial has accelerated and a Veyonda dose of 1200mg is safe and well tolerated in combination with Opdivo. This trial is exciting as it is our first investigation into the combination of Veyonda with an immuno-oncology drug. Immuno-oncology is a relatively new but growing cancer therapy market, and patients who are resistant to these drugs are generally left with very few treatment options. Our overarching goal is to improve this situation."

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its lead clinical-stage drug candidate Veyonda®, plus two innovative technology platforms – Chroma™ (oncology) and Sofra™ (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

About IONIC

IONIC is an investigator-initiated pilot-study exploring the safety and efficacy signals of Veyonda in combination with Bristol Myers Squibb's immune checkpoint inhibitor (ICI) Opdivo® (nivolumab) for patients with solid tumours.

ICIs such as nivolumab have had impressive results in some patients with a limited number of cancer types, but remain inactive in most cancers. The aim of the study is to increase the activity of nivolumab by using Veyonda to overcome tumour resistance to ICI therapy.

There are two cohorts: one cohort of patients that has progressed on ICIs and one cohort with patients who are treatment-naïve to ICIs. Both cohorts are enrolled in parallel. Approximately 30 patients at a number of Australian sites are targeted to participate in the study.

The study involves an initial dose escalation phase, followed by dose expansion.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements

to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.